Xeris Biopharma (NASDAQ:XERS) Stock Price Expected to Rise, HC Wainwright Analyst Says

Xeris Biopharma (NASDAQ:XERS) had its price target upped by HC Wainwright from $6.00 to $6.60 in a research note issued to investors on Monday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. HC Wainwright’s price target points to a potential upside of 109.52% from the stock’s current price. HC Wainwright also issued estimates for Xeris Biopharma’s FY2027 earnings at $0.19 EPS.

Separately, Piper Sandler cut shares of Xeris Biopharma from an “overweight” rating to a “neutral” rating and set a $3.00 price objective on the stock. in a research report on Monday.

Xeris Biopharma Trading Down 4.0 %

Xeris Biopharma stock opened at $3.15 on Monday. The firm has a market capitalization of $469.35 million, a PE ratio of -7.00 and a beta of 2.70. Xeris Biopharma has a 1-year low of $1.46 and a 1-year high of $3.64. The firm’s 50 day simple moving average is $2.98 and its 200 day simple moving average is $2.52.

Hedge Funds Weigh In On Xeris Biopharma

Institutional investors have recently modified their holdings of the company. Intech Investment Management LLC purchased a new stake in Xeris Biopharma in the third quarter worth approximately $130,000. Connor Clark & Lunn Investment Management Ltd. purchased a new stake in shares of Xeris Biopharma in the 3rd quarter valued at $237,000. China Universal Asset Management Co. Ltd. grew its holdings in shares of Xeris Biopharma by 64.5% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 28,657 shares of the company’s stock valued at $82,000 after purchasing an additional 11,239 shares during the last quarter. Goldstein Advisors LLC raised its position in Xeris Biopharma by 19.7% in the 3rd quarter. Goldstein Advisors LLC now owns 30,425 shares of the company’s stock worth $87,000 after purchasing an additional 5,000 shares during the period. Finally, Wealth Enhancement Advisory Services LLC bought a new stake in Xeris Biopharma in the third quarter worth $35,000. 42.75% of the stock is currently owned by institutional investors.

Xeris Biopharma Company Profile

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.